Metabolic FingerPrinting
MetaPrint
1 other identifier
observational
10,000
2 countries
5
Brief Summary
The MetaPrint study aims to characterize the metabolic fingerprint of genetic diseases in order to enhance knowledge on the physiological disease status and establish so new tools for diagnosing, monitoring and personalizing treatment of genetic diseases.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Longer than P75 for all trials
5 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2021
CompletedFirst Submitted
Initial submission to the registry
March 21, 2022
CompletedFirst Posted
Study publicly available on registry
March 31, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2026
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2026
CompletedMarch 31, 2022
March 1, 2022
5 years
March 21, 2022
March 30, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Number of newly identified, disease-specific Metabolic Fingerprints
Plasma-derived metabolite profiles that are specific for a particular genetic disease in comparison to healthy controls and other genetic diseases
5 years
Study Arms (1)
Subjects with a genetic disease
Interventions
Eligibility Criteria
All subjects with a confirmed genetic disease as well as their first degree family members can participate in the study.
You may qualify if:
- Informed consent is obtained from the participant or from the parent/ legal guardian
- The participant is 2 months or older
- The participant is diagnosed with a genetic disease
- The participant is a first degree relative of a subject diagnosed with a genetic disease
You may not qualify if:
- Informed consent is not obtained from the participant or from the parent/ legal guardian
- The participant is younger than 2 months
- The participant is not diagnosed with a genetic disease
- The participant is not a first degree relative of a subject diagnosed with a genetic disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Arcensus GmbHlead
Study Sites (5)
University Hospital Center Mother Teresa
Tirana, 1000, Albania
The Children's hospital & Institute of child health
Lahore, Punjab Province, 54000, Pakistan
Pakistan Institute of Medical Sciences (PIMS)
Islamabad, 4485, Pakistan
Children's Hospital & The Institute of Child Health
Multan, 60000, Pakistan
Khyber institute of Child Health and Children Hospital (KICH)
Peshawar, 25100, Pakistan
Biospecimen
Blood samples will be collected from all participants.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 21, 2022
First Posted
March 31, 2022
Study Start
March 1, 2021
Primary Completion
March 1, 2026
Study Completion
March 1, 2026
Last Updated
March 31, 2022
Record last verified: 2022-03